Monday, June 26, 2017
QuintilesIMS to buy DrugDev
QuintilesIMS to buy DrugDev
Celebrating its 10-year anniversary, Cenduit, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is showcasing its solutions and expertise as an interactive response technology (IRT) specialist at DIA 2017, June 19-21 in Chicago. Cenduit’s new CEO Sam Osman will be present at the show, where the company will be launching its newest rapid study build software, Quantum Interactive.
During the past decade, advances in personalized medicine and immuno-oncology have fueled a major shift in treatment of cancer, according to new research from the QuintilesIMS Institute. Since 2011, 68 novel therapies have been approved across 22 cancer indications globally. These developments have led to more options as well as greater access and improved outcomes for patients—especially for those individuals with metastatic disease.
In a QuintilesIMS report, various aspects of the market for medicines in the U.S. is highlighed—panning aggregate spending, key medicine categories, volumes, patient cost exposure, as well as an outlook to 2021. The report seeks to provide appropriate context and perspective around the complex factors that drive the level of spending on medicines and their role in our healthcare system.
QuintilesIMS, a provider of information, technology services and contract research to the life sciences industry, announced an alliance with Salesforce, a CRM company and Intelligent Customer Success Platform, to offer life sciences companies new capabilities to move treatments more efficiently and effectively, from molecule to market.
The Domestic Research Enhancement Act of 2017 (H.R. 1234), which modernizes the R&D tax credit to recognize the essential role contract research now plays in the development of new pharmaceuticals, biologics and medical devices, has been introduced by Rep. Pat Meehan (R-PA) and co-sponsors Rep. George Holding (R-NC) and G.K. Butterfield (D-NC).
PSI, INC, Chiltern take top site ratings
QuintilesIMS has once again been named to FORTUNE magazine’s “World’s Most Admired Companies” list. The 2017 listing marks the third consecutive year the company has been recognized by FORTUNE as a most admired company.
Drug development sponsors and CROs increasingly recognize the importance of investigative sites having a stronger, more respected voice in the clinical research community and have begun adopting initiatives designed to incorporate site viewpoints into improving clinical development processes.
Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33% from 2016 levels, even as annual growth moderates from the record pace set in 2014 and 2015, according to new research released by the QuintilesIMS Institute. While historically large numbers of high-quality new medicines will emerge from the R&D pipeline in the next five years, pricing and market access pressures, lower volume growth in pharmerging markets and greater savings from patent expiries will contribute to the lower rate of growth.